Eugene Davis
appointed Eugene Davis and John T. Young, Jr. to the Board
Highest-materiality recent filing
Inotiv enters $65.5M DIP financing, Nasdaq to delist shares June 11; expects total equity loss
DIP facility: $25M new money term loans + $40.5M roll-up of prepetition bridge loans; interest at Adjusted Term SOFR + 11.5%.
Inotiv files prepackaged Chapter 11; to cut debt by $326M, cancel existing equity
Debt reduction of approx. $326M through conversion of funded debt into reorganized company equity.
Company failed to make $2.139M interest payment on 3.25% Convertible Senior Notes due 2027 on April 15, 2026.
Entered $40M bridge facility; borrowed $27.5M to repay all outstanding revolving loans (~$14.3M) and terminate revolver commitments.
Inotiv receives waiver of minimum liquidity covenant for May 2026 test dates
Lenders waived minimum liquidity covenant for May 1 and May 8, 2026 test dates.
Inotiv obtains waiver of minimum liquidity covenant for April 2026 test dates
Lenders under Credit Agreement (Nov 5, 2021) granted waiver of min liquidity covenant for Apr 17 and Apr 24, 2026 test dates.
Inotiv obtains waiver of minimum liquidity covenant for two April 2026 test dates
Lenders waived minimum liquidity covenant for April 3 and April 10, 2026 test dates under Credit Agreement.
Inotiv receives waiver of minimum liquidity covenant for March 20 and 27, 2026 test dates
Lenders waived minimum liquidity covenant for March 20 and March 27, 2026 test dates under the Credit Agreement.
Inotiv obtains lender waiver of minimum liquidity covenant for March 2026 test dates
Lenders waived minimum liquidity covenant for March 6 and March 13, 2026 test dates.
Inotiv Q1 FY2026 revenue up 0.8% to $120.9M; operating loss widens to $16.3M
Revenue $120.9M (+0.8% YoY); DSA segment up 12% to $48M, RMS down 5.4% to $72.9M.
Court preliminarily approves Inotiv derivative settlement; $2.49M from insurance for company benefit
Preliminary approval order issued Jan 7, 2026; final hearing set for Mar 18, 2026 at 9:00 a.m.
Inotiv receives Nasdaq notice for non-compliance with minimum bid price rule
Received Nasdaq notification on Dec 31, 2025 for failing to maintain minimum $1.00 bid price for 30 consecutive business days.
Inotiv Q4 revenue $138.1M (+5.9% YoY); operating loss down 48.5% to $6.8M
Total revenue $138.1M in Q4 FY2025, up 5.9% YoY; DSA revenue $51.6M (+15.7%), RMS $86.5M (+0.8%).
Inotiv prelim Q4 revenue $137.5-138.5M; full year $512.5-513.5M; DSA awards up 60% YoY
Preliminary Q4 FY2025 revenue $137.5-138.5M, improving over prior year; full year $512.5-513.5M.
Inotiv settles securities class action for $8.75M, derivative settlement with governance changes
$8.75M cash settlement to resolve securities class action; funded by available insurance.
Inotiv reports ransomware attack encrypting systems; business operations disrupted
Threat actor gained unauthorized access and encrypted certain company systems on August 8, 2025.
Inotiv reports Q3 FY2025 revenue up 23.5% to $130.7M; net loss narrows to $17.6M
Quarterly revenue $130.7M (+23.5% YoY); DSA $48.2M (+8.9%), RMS $82.5M (+34.1%).
Inotiv Q3 FY2025 revenue up 23.5% to $130.7M; net loss narrows to $17.6M
Revenue $130.7M, +23.5% YoY; DSA $48.2M (+8.9%), RMS $82.5M (+34.1%).
SEC closes FCPA investigation into Inotiv's primate imports, no enforcement action
On June 2, 2025, SEC Division of Enforcement notified Inotiv it will not recommend enforcement action.
Inotiv holds 2025 Investor Day on May 29, 2025
Investor Day occurred at 10:00 a.m. ET with management presentation.
Inotiv Q2 revenue up 4.4% to $124.3M; net loss narrows to $14.9M from $48.1M
Revenue $124.3M in Q2 FY2025 (+4.4% YoY); YTD revenue $244.2M (-4.1% YoY).
Inotiv shareholders approve 2.25M share increase to 2024 equity plan at annual meeting
Shareholders approved amendment adding 2,250,000 shares to the 2024 Equity Incentive Plan (9,336,190 for, 287,815 against, 12,474,838 broker non-votes).
Inotiv settles lagoon design lawsuit with Freese and Nichols for $7.55M
Settlement resolves claims over FNI's failure to design adequate wastewater lagoon at Alice, TX facility.
Inotiv Q1 FY2025 revenue $119.9M (-11.5%); net loss widens to $27.6M
Revenue declined 11.5% to $119.9M; RMS segment down 15.1%, DSA down 4.2%.
Inotiv prices public offering of 6M shares at $4.25; expects ~$24M net proceeds
Priced 6M share offering at $4.25 each; underwriter has 30-day option for up to 900k additional shares.
Inotiv FY2024 revenue down 14.3% to $490.7M; net loss $108.9M; adj. EBITDA falls sharply
Q4 FY2024 revenue $130.4M (-7.3% YoY, +23.3% sequentially); net loss $18.9M vs $8.7M loss YoY.
Inotiv amends credit agreement, issues $22.6M 15% PIK notes, gets covenant relief through June 2025
$22.6M of 15% PIK notes due 2027 issued for $17M cash and $8.3M convertible note cancellation.
Inotiv signs $50M ATM equity facility with Jefferies, 3% commission
$50M of common shares may be sold from time to time via Jefferies as agent in at-the-market offerings.
Inotiv Q3 FY2024 revenue down 32.8% to $105.8M; net loss $26.1M; adjusted EBITDA $0.1M
Revenue fell 32.8% YoY to $105.8M; RMS segment down 44.4% on lower NHP demand and pricing.
Inotiv subsidiaries plead guilty in DOJ canine-facility probe; total payments exceed $35M
Envigo RMS pleaded guilty to misdemeanor conspiracy to violate Animal Welfare Act; EGSI pleaded guilty to felony Clean Water Act conspiracy.
Inotiv Q2 revenue down 21.5%, net loss $48.1M includes $26.5M DOJ charge; withdraws FY2024 guidance
Q2 FY2024 revenue $119.0M (-21.5% YoY); net loss $48.1M vs $9.6M loss prior year.
Inotiv shareholders approve 2024 Equity Incentive Plan, re-elect three directors
2024 Plan authorizes up to 1.5M new shares plus rollover from 2018 Plan; no further grants under 2018 Plan.
Inotiv reports Q1 FY2024 revenue up 10.3% to $135.5M; net loss narrows to $15.8M from $86.9M
Adjusted EBITDA turned positive to $9.6M (7.1% of revenue) vs. -$5.5M in prior year.
Inotiv reports FY2023 revenue $572.4M (+4.5%), adj. EBITDA $65.8M; FY2024 guidance $580-590M
Q4 revenue $140.7M (-6.5% YoY) with DSA +13.6% to $50.2M, RMS -14.9% to $90.5M.
Inotiv appoints Terry Coelho to board, replacing Richard Johnson effective Oct 16, 2023
Richard A. Johnson resigned as director; Terry Coelho appointed as Class II director.
Inotiv Q3 revenue $157.5M (-8.8% YoY); cuts FY2023 guidance to at least $570M
Q3 revenue $157.5M, down 8.8% YoY; net income $0.4M vs loss $(3.6M) in Q3 FY2022.
Inotiv Q2 FY2023 revenue $151.5M (+8% YoY); net loss $(9.6)M; cuts FY23 Adj EBITDA guidance to $70M
Revenue $151.5M in Q2 FY2023, up 8% from $140.3M; DSA segment revenue up 20.2%.
Inotiv shareholders elect Richard Johnson and Nigel Brown as Class II directors
Johnson received 6,032,125 for and 3,325,163 withheld; Brown received 8,432,012 for and 925,276 withheld.
Revenue rose 45.8% YoY to $122.8M, driven by acquisitions in DSA (+$8.3M) and RMS (+$30.3M).
Scott Cragg resigns from board effective Jan 23, 2023; resignation not due to any disagreement.
Inotiv Q4 FY2022 net loss $243.6M includes $236M goodwill impairment; sees FY2023 rev ≥$580M
Full year revenue $547.7M (up from $89.6M); net loss $(337.3)M vs net income $10.9M prior year.
Second Amendment extends deadline to provide audited FY2022 financials to Jan. 13, 2023 or 10-K filing date.
Inotiv delays FY2022 results; preliminary revenue $547.7M; NHP import probe ongoing
Preliminary FY2022 revenue ~$547.7M (up from $89.6M in FY2021); DSA backlog $147.2M.
Closing two isolator facilities in Indianapolis, IN, consolidating into existing U.S. facilities by end of fiscal year 2023.
Inotiv's primary NHP supplier employees criminally charged with illegal import conspiracy
USAO-SDFL charged employees of Inotiv's main NHP supplier and two Cambodian officials with conspiracy to illegally import NHPs from Dec 2017 to Jan 2022.
Inotiv adopts bylaw amendments allowing remote shareholder meetings and updating proxy procedures
Bylaws now permit remote-only shareholder meetings via electronic communication under Indiana law.
Bylaws amended effective Nov 2, 2022; now allow shareholder meetings solely by remote communication.
Inotiv appoints Brennan Freeman as VP Finance and Corporate Controller, principal accounting officer
Freeman, 35, appointed VP Finance and Corporate Controller effective October 25, 2022; will serve as principal accounting officer.
Inotiv borrows full $35M delayed draw term loan at initial rate of 9.75%
Borrowed entire $35.0M delayed draw term loan under existing credit agreement.
Inotiv Q3 FY2022 revenue rises to $172.7M; raises FY2022 revenue guidance to at least $550M
Q3 FY2022 revenue $172.7M vs $22.9M a year ago; DSA revenue $49.2M (+114.8% YoY), RMS $123.4M from nil.
appointed Eugene Davis and John T. Young, Jr. to the Board
appointed Eugene Davis and John T. Young, Jr. to the Board
The Board has appointed Terry Coelho to the Board, effective October 16, 2023, to serve as a Class II director of the Company for a term ending at the Annual Meeting of Shareholders in 2026.
Richard A. Johnson, Ph.D. previously tendered his resignation as a director of the Company, to be effective automatically upon notice to Dr. Johnson from the Company that the Board of Directors (the "Board") is prepared to elect an approved director as provided in the Shareholders Agreement.
the Board has appointed Mr. Landman to the Board, effective as of 12:00 a.m. ET on January 24, 2023, to serve as a Class III director of the Company for a term ending at the Annual Meeting of Shareholders in 2024. Mr. Landman was also appointed to serve as a member and the Chair of the Compensation Committee of the Board.
On January 17, 2023, Scott Cragg, a member of the Board of Directors (the “Board”) of Inotiv, Inc. (the “Company”), notified the Company of his decision to resign from the Board.
On October 25, 2022, the Board of Directors of Inotiv, Inc. (the “Company”) appointed Brennan Freeman, age 35, as Vice President – Finance and Corporate Controller of the Company.
Ms. Taylor continues to serve as the Company’s Chief Financial Officer and principal financial officer.
James Harkness, the Company’s Chief Operating Officer, Research Models & Services, will be retiring from the Company, effective on September 30, 2022.
On November 4, 2021, the Board of Directors of the Company (the “Board”) expanded the size of the Board to seven members and appointed Nigel Brown, Ph.D. and Scott Cragg to the Board pursuant to the terms of the Shareholders Agreement, which is described in detail in Item 1.01 above.
On November 5, 2021, Richard A. Johnson, Ph.D. tendered his resignation as a director of the Company, to be effective automatically upon notice to Dr. Johnson from the Company that the Board is prepared to elect the Approved Director as provided in the Shareholders Agreement.
On November 4, 2021, the Board of Directors of the Company (the “Board”) expanded the size of the Board to seven members and appointed Nigel Brown, Ph.D. and Scott Cragg to the Board pursuant to the terms of the Shareholders Agreement, which is described in detail in Item 1.01 above.
Max materiality 1.00 · Median 0.70 · Most common event earnings